Skip to content
Open access

Efficient experimental characterization of the GPCRome via deep receptor scanning

Aug 2026 · Nature Communications · Vol 17 · 0 citations · 64 references
Medicine

TL;DR

A versatile “deep receptor scanning” platform is introduced that can be used to experimentally characterize 766 human GPCRs and 174 known GPCR splice variants in parallel and show that many highly-expressed receptors exhibit systematic differences in hydrophobicity and secondary structure.

Abstract

G protein-coupled receptors (GPCRs) mediate a variety of signaling pathways and represent the most common class of pharmaceutical target. While advances in structural biochemistry have provided deep functional insights into key receptors, many of the 800+ human GPCRs remain understudied. We introduce a versatile “deep receptor scanning” platform that can be used to experimentally characterize 766 human GPCRs and 174 known GPCR splice variants in parallel. We use this platform to quantitatively characterize the relative abundance of canonical and alternative receptor transcripts, their translational efficiency, and the plasma membrane expression of each receptor in the context of a recombinant pool of HEK293T cells expressing individual GPCRs. We then employ machine learning to identify specific structural features that are strongly associated with variations in GPCR expression. Our results show that many highly-expressed receptors exhibit systematic differences in hydrophobicity and secondary structure. This experimental platform and informatic approach are compatible with a variety of assays and can be used to efficiently explore the biochemical and pharmacological properties of the GPCRome. Here, the authors introduce deep receptor scanning methodology to enable characterization of 940 human GPCRs in parallel. This approach can be coupled to a variety of assays to systematically profile the activity and pharmacology of nearly all human GPCRs.

Read PDF

Similar papers

Aug 2026

Universal pipeline for high-resolution GPCR structure determination

A universal pipeline that integrates an in silico fusion construct screening program, NOAH, with a de novo designed fusion protein to reduce construct optimization effort and enable rapid high-resolution G-protein-coupled receptor structure determination for drug discovery is introduced.

Asato Kojima, Kouki Kawakami, Naoya Kobayashi et al. · 0 citations
Oct 2026

ESCAPE enables receptor-specific chemogenetic dissection of GPCR signaling.

G-protein-coupled receptors (GPCRs) are essential mediators of cellular processes, and their dysfunction is implicated in various diseases. Although pharmacological approaches are powerful for elucidating GPCR functions, careful consideration of potential off-target effects remains crucial. Here, we present an off-targ...

Yuma Matsuoka, Hajime Inoue, Tatsuki Hori et al. · 0 citations
Open access Sep 2026

An Excelled Trifluorinated Probe for GPCR Conformational Quantification

G protein-coupled receptors (GPCRs) represent the largest membrane protein family in the human body and the major targets of FDA-approved medications. Unlike some other physiological proteins, GPCRs are highly plastic and often exist as collections of conformational ensembles in the environment to exert their function....

Xu-Dong Wang, Yu-Long Cao, Wen-Jie Zhao et al. · 0 citations
Review Open access Sep 2026

Tools to investigate class B1 GPCR conformational landscapes with cryo-EM and beyond.

G protein-coupled receptors (GPCRs) are membrane proteins that act as signal transducers across cell membranes. Class B1 GPCRs, a subset of 15 receptors activated by peptide hormones, are involved in important physiological processes and diseases, making them a popular target for drug development. GPCRs are dynamic pro...

Theodore J. Nettleton, P. M. Sexton, D. Wootten et al. · 0 citations
Open access Sep 2026

GPCR antagonism via rewiring of receptor trafficking and degradation

G protein–coupled receptors (GPCRs) represent one of the most important yet incompletely addressed classes of therapeutic targets1. Here, we report a novel strategy for functional GPCR antagonism via bispecific antibody-mediated endocytosis and lysosomal degradation. GPCR-TfR1 targeting chimeras (GTACs) achieve potent...

Kaitlin Rhee, L. Shue, Akimasa Adachi et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.